N-hydroxypyridone derivatives of ciclopirox for antifungal applications

Overview

This research presents a focused library of ten N-hydroxypyridone (HPO) derivatives synthesized from ciclopirox, an established topical antifungal agent. The project aims to establish a preliminary structure-activity relationship (SAR) that connects chemical modifications of the ciclopirox scaffold to both antifungal potency and mammalian cell toxicity. The work addresses a critical gap in antifungal drug development: ciclopirox's precise molecular target has not been definitively identified, yet the difficulty of generating resistant fungal mutants suggests it acts on essential biological processes. Preliminary evidence indicates these derivatives may interfere with iron-dependent enzymes, a mechanism that could differentiate them from existing antifungal classes and reduce cross-resistance concerns.

The value proposition for industry partners lies in accessing a characterized compound series with potential applications in treating fungal infections, including difficult-to-treat pathogens such as Cryptococcus neoformans and Candida albicans. The research provides a foundation for further optimization toward clinical candidates or topical therapeutic formulations.

Technical specifications

• Core chemistry: Ten N-hydroxypyridone derivatives built upon the ciclopirox scaffold, a clinically validated antifungal pharmacophore.
• Proposed mechanism: Interference with iron-dependent enzymes, distinguishing this series from azoles, echinocandins, and polyenes currently dominating antifungal therapy.
• Biological evaluation: Antifungal efficacy testing against Cryptococcus neoformans and Candida albicans, with parallel mammalian cell culture toxicity assessment to establish a therapeutic index.
• Differentiation: Prior resistance studies in Candida albicans suggest ciclopirox targets essential enzymes or processes, implying a low propensity for rapid resistance development.
• Research stage: Early-stage medicinal chemistry with SAR exploration; target identification remains an open research question.

Technology readiness level

This technology is at an early discovery stage (TRL 2–3). The compound library has been synthesized, and preliminary biological evaluation is underway to characterize antifungal activity and mammalian toxicity. The enzyme target has not yet been confirmed, and additional medicinal chemistry optimization, target deconvolution, and in vivo validation would be required before translational development. The work represents a promising starting point for partnership in antifungal drug discovery rather than a development-ready asset.